Biotech Specialty Pharma

Spherix Incorporated

6430 Rockledge Drive #503
Bethesda, MD 20817 USA
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Innovative biopharmaceutical products and consulting services.

Management Claire L. Kruger, CEO, COO; Robert A. Lodder, President; Robert L. Clayton, CFO, Treasurer; Katherine M. Brailer, Corporate Secretary and Director of Administrative Services

Click here for Financial Data
Keywords: SPEX, Type 2 diabetes, triglycerides, clinical, biotechnology, pharmaceutical companies


Updated: Dec. 08, 2014


Spherix develops innovative biopharmaceutical products and provides technical and regulatory consulting services through subsidiaries Biospherics and Spherix Consulting. Biospherics has completed a gl......view more

Products / Services

D-tagatose is a novel, small molecule that has shown human proof of concept as a glycemic control and anti-hypertriglyceridemia agent in a Phase 2 and an initial Phase 3 clinical trial in Type II Diab......view more

Technology / Differentiation

SPX-106, is one of five small, non-carbohydrate molecules in-licensed by Spherix last year. D-tagatose is a novel, small molecule that has shown human proof of concept as a glycemic control agent in...view more

Market / Customers

Tagatose has the potential to compete in the multi-billion dollar dyslipidemic and diabetic markets.......view more


Spherix is seeking development and commercialization agreements and acquisitions to support continued development of tagatose in two different indications with two different dose/dose forms: (1) Type...view more


Spherix Incorporated was launched in 1967 as a scientific research company under the name Biospherics Research. The Company now leverages its scientific and technical expertise and experience through...view more